EHA 2020 – PET-guided treatment may allow many patients with Hodgkin lymphoma to avoid radiotherapy


  • Ben Gallarda
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Standard of care radiotherapy (RT) was omitted in patients with early-stage unfavorable Hodgkin lymphoma (HL) responsive to chemotherapy (CT) without loss of treatment efficacy.
  • Positron emission tomography (PET) assessment of CT response in these patients guided the decision to omit RT.

Why this matters

  • Routine use of RT puts these typically younger patients at a risk for long-term side effects, including an increased risk for secondary cancers.

Study design

  • Phase 3 international randomized controlled prospective trial of 1100 patients aged 18-60 years with newly diagnosed unfavorable HL.
  • Patients were assigned to combined modality treatment (CMT): 4 cycles of CT followed by 30 Gy involved-field RT or PET-guided treatment, which omitted RT in patients with Deauville score (DS)
  • Funding: Deutsche Krebshilfe, German Cancer Aid.

Key results

  • 979 patients had confirmed PET results: 66.5% were PET-negative, 24.3% had DS3, and 9.2% DS4.
  • Overall 5-year progression-free survival (PFS):
    • CMT group (n=428): 97.3%.
    • PET-guided treatment (n=477): 95.1%.
    • Difference: −2.2% (95% CI, −5.3% to 0.9%), excluding prespecified lower noninferiority margin of −8%.
  • 5-year PFS in PET-negative patients:
    • CMT group, with RT: 97.7%.
    • PET-guided group, no RT: 95.9%.
  • PET-positivity was confirmed as a significant risk factor for disease progression.

Limitations

  • Low number of fatal events.

Outlook

  • Dr Borchmann, who presented these findings commented that “PET-guided 2+2 chemotherapy is the new GHSG [German Hodgkin Study Group] standard of care,” and that “Most patients with this disease will not need radiotherapy any longer.”